Avid Bioservices (NASDAQ:CDMO) has earned an average recommendation of “Buy” from the six ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $4.00.
Several brokerages have recently issued reports on CDMO. Noble Financial reiterated a “buy” rating on shares of Avid Bioservices in a research report on Friday, January 5th. ValuEngine lowered shares of Avid Bioservices from a “sell” rating to a “strong sell” rating in a research report on Monday, April 2nd. Zacks Investment Research upgraded shares of Avid Bioservices from a “sell” rating to a “hold” rating in a research report on Tuesday, February 27th. Wells Fargo began coverage on shares of Avid Bioservices in a research report on Thursday, March 15th. They issued an “outperform” rating on the stock. Finally, First Analysis began coverage on shares of Avid Bioservices in a research report on Tuesday, March 13th. They issued an “overweight” rating and a $4.00 target price on the stock.
Shares of NASDAQ CDMO traded down $0.10 during trading on Monday, hitting $3.28. The company had a trading volume of 629,075 shares, compared to its average volume of 391,050. Avid Bioservices has a fifty-two week low of $2.24 and a fifty-two week high of $5.78. The firm has a market cap of $187.77, a price-to-earnings ratio of -3.73 and a beta of 2.23.
Avid Bioservices (NASDAQ:CDMO) last announced its earnings results on Monday, March 12th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.09). Avid Bioservices had a negative net margin of 46.62% and a negative return on equity of 57.49%. The company had revenue of $6.82 million during the quarter, compared to analyst estimates of $8.95 million. equities analysts expect that Avid Bioservices will post -0.63 EPS for the current fiscal year.
The firm also recently declared a dividend, which was paid on Monday, April 2nd. Investors of record on Monday, March 19th were given a dividend of $0.6563 per share. The ex-dividend date of this dividend was Friday, March 16th.
In other Avid Bioservices news, Director Mark R. Bamforth purchased 50,000 shares of the stock in a transaction that occurred on Thursday, February 15th. The shares were purchased at an average cost of $2.25 per share, for a total transaction of $112,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.53% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Brokerages Set Avid Bioservices (CDMO) PT at $4.00” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/16/brokerages-set-avid-bioservices-cdmo-pt-at-4-00.html.
Avid Bioservices Company Profile
Avid Bioservices, Inc operates as a contract development and manufacturing organization focusing on the development and cGMP manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, and cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.
Receive News & Ratings for Avid Bioservices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avid Bioservices and related companies with MarketBeat.com's FREE daily email newsletter.